File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B

TitleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B
Authors
KeywordsAntiviral Therapy
Hepatitis B Virus
Nucleos(T)Ide Analogue
Issue Date2012
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cgh
Citation
Clinical Gastroenterology And Hepatology, 2012 How to Cite?
AbstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.
Persistent Identifierhttp://hdl.handle.net/10722/163490
ISSN
2014 Impact Factor: 7.896
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorPan, CQen_US
dc.contributor.authorTong, Men_US
dc.contributor.authorKowdley, KVen_US
dc.contributor.authorHu, Ken_US
dc.contributor.authorChang, Ten_US
dc.contributor.authorLai, Cen_US
dc.contributor.authorYoon, SKen_US
dc.contributor.authorLee, SSen_US
dc.contributor.authorCohen, Den_US
dc.contributor.authorTang, Hen_US
dc.contributor.authorTsai, Nen_US
dc.date.accessioned2012-09-05T05:32:07Z-
dc.date.available2012-09-05T05:32:07Z-
dc.date.issued2012en_US
dc.identifier.citationClinical Gastroenterology And Hepatology, 2012en_US
dc.identifier.issn1542-3565en_US
dc.identifier.urihttp://hdl.handle.net/10722/163490-
dc.description.abstractThere are limited data on the effects of long-term entecavir therapy in Asian patients with chronic hepatitis B (CHB). We performed a post hoc analysis of 94 Asian hepatitis B e antigen-positive (HBeAg+), nucleos(t)ide analogue-naive patients who received 5 years of therapy with entecavir (up to 2 years in study ETV-022 and the remainder in study ETV-901). Among patients completing week 240, 95% (63 of 66) had levels of hepatitis B virus DNA <300 copies/mL, and 76% (50 of 66) had normalized levels of alanine aminotransferase. In addition to patients who achieved a serologic response during ETV-022, a further 40% (26 of 65) achieved HBeAg loss, and 18% (12 of 65) underwent HBeAg seroconversion through year 5 of entecavir therapy. No resistance to entecavir was detected, and the safety profile was consistent with previous reports. The long-term efficacy and safety of entecavir are therefore comparable between Asians and the overall population of HBeAg+ patients with CHB. © 2012 AGA Institute.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/cghen_US
dc.relation.ispartofClinical Gastroenterology and Hepatologyen_US
dc.subjectAntiviral Therapyen_US
dc.subjectHepatitis B Virusen_US
dc.subjectNucleos(T)Ide Analogueen_US
dc.titleHigh Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis Ben_US
dc.typeArticleen_US
dc.identifier.emailLai, C:hrmelcl@hku.hken_US
dc.identifier.authorityLai, C=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.cgh.2012.03.016en_US
dc.identifier.pmid22475742-
dc.identifier.scopuseid_2-s2.0-84865319280en_US
dc.identifier.hkuros208887-
dc.identifier.isiWOS:000308578400020-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridPan, CQ=8431195300en_US
dc.identifier.scopusauthoridTong, M=7202033792en_US
dc.identifier.scopusauthoridKowdley, KV=26643305700en_US
dc.identifier.scopusauthoridHu, K=55213827000en_US
dc.identifier.scopusauthoridChang, T=7404725147en_US
dc.identifier.scopusauthoridLai, C=7403086396en_US
dc.identifier.scopusauthoridYoon, SK=7404036291en_US
dc.identifier.scopusauthoridLee, SS=7601405566en_US
dc.identifier.scopusauthoridCohen, D=35475416000en_US
dc.identifier.scopusauthoridTang, H=55214347700en_US
dc.identifier.scopusauthoridTsai, N=7006824415en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats